AIM: The aim is to evaluate the impact of cisplatin dose modification on outcomes of human papillomavirus (HPV)-related (HPV+) and HPV-unrelated (HPV-) locally advanced head and neck cancer (LAHNC) treated with chemoradiotherapy (CRT). PATIENTS AND METHODS: A pooled analysis was conducted of stage III/IV oropharyngeal cancer (OPC), carcinoma of unknown primary (CUP) and laryngo-hypopharyngeal cancer (LHC) patients treated with single-agent cisplatin CRT in 2000-2012 from two tertiary academic cancer centres. HPV status was determined by p16 staining and/or in situ hybridisation. LHC was assumed to be HPV-. Unknown HPV status OPC/CUPs were excluded. Overall survival (OS) was calculated. Multivariable analysis (MVA) evaluated the impact of cisplatin dose intensity on survival for HPV+ and HPV- cohorts separately. RESULTS: A total of 404 HPV+ and 255 HPV- LAHNC (481 OPC, 18 CUP, 160 LHC) patients were included. Median follow-up was 4.3 (0.5-11.9) years. Three-year OS for cisplatin <200, =200, and >200 mg/m2 subgroups were 52%, 60%, and 72% (P = 0.001) for the HPV- and 91%, 90%, and 91% (P = 0.30) for the HPV+ patients. MVA confirmed a survival benefit with cisplatin >200 mg/m2 for the HPV- (hazard ratio [HR] 0.5, 95% confidence interval [CI]: 0.3-0.7, P < 0.001) but not for HPV+ (HR 0.6, 95% CI: 0.4-1.1, P = 0.104). There was a superior OS trend in the HPV+ T4 or N3 high-risk subset (N = 107) with cisplatin >200 mg/m2 (HR 0.5, 95% CI: 0.2-1.1, P = 0.07). CONCLUSIONS: A survival benefit of cisplatin dose >200 mg/m2 is evident for HPV- LAHNC patients, but not for HPV+ cohort overall, although the T4 or N3 subset may benefit from a higher cumulative cisplatin dose.
AIM: The aim is to evaluate the impact of cisplatin dose modification on outcomes of human papillomavirus (HPV)-related (HPV+) and HPV-unrelated (HPV-) locally advanced head and neck cancer (LAHNC) treated with chemoradiotherapy (CRT). PATIENTS AND METHODS: A pooled analysis was conducted of stage III/IV oropharyngeal cancer (OPC), carcinoma of unknown primary (CUP) and laryngo-hypopharyngeal cancer (LHC) patients treated with single-agent cisplatin CRT in 2000-2012 from two tertiary academic cancer centres. HPV status was determined by p16 staining and/or in situ hybridisation. LHC was assumed to be HPV-. Unknown HPV status OPC/CUPs were excluded. Overall survival (OS) was calculated. Multivariable analysis (MVA) evaluated the impact of cisplatin dose intensity on survival for HPV+ and HPV- cohorts separately. RESULTS: A total of 404 HPV+ and 255 HPV- LAHNC (481 OPC, 18 CUP, 160 LHC) patients were included. Median follow-up was 4.3 (0.5-11.9) years. Three-year OS for cisplatin <200, =200, and >200 mg/m2 subgroups were 52%, 60%, and 72% (P = 0.001) for the HPV- and 91%, 90%, and 91% (P = 0.30) for the HPV+ patients. MVA confirmed a survival benefit with cisplatin >200 mg/m2 for the HPV- (hazard ratio [HR] 0.5, 95% confidence interval [CI]: 0.3-0.7, P < 0.001) but not for HPV+ (HR 0.6, 95% CI: 0.4-1.1, P = 0.104). There was a superior OS trend in the HPV+ T4 or N3 high-risk subset (N = 107) with cisplatin >200 mg/m2 (HR 0.5, 95% CI: 0.2-1.1, P = 0.07). CONCLUSIONS: A survival benefit of cisplatin dose >200 mg/m2 is evident for HPV- LAHNC patients, but not for HPV+ cohort overall, although the T4 or N3 subset may benefit from a higher cumulative cisplatin dose.
Authors: Kayla L Conner; Asra N Shaik; Elmira Ekinci; Seongho Kim; Julie J Ruterbusch; Michele L Cote; Steve M Patrick Journal: DNA Repair (Amst) Date: 2020-01-16
Authors: Joshua M Bauml; Ravi Vinnakota; Yeun-Hee Anna Park; Susan E Bates; Tito Fojo; Charu Aggarwal; Sewanti Limaye; Nevena Damjanov; Jessica Di Stefano; Christine Ciunci; Eric M Genden; Juan P Wisnivesky; Rocco Ferrandino; Ronac Mamtani; Corey J Langer; Roger B Cohen; Keith Sigel Journal: J Natl Cancer Inst Date: 2019-05-01 Impact factor: 13.506
Authors: Petr Szturz; Kristien Wouters; Naomi Kiyota; Makoto Tahara; Kumar Prabhash; Vanita Noronha; Ana Castro; Lisa Licitra; David Adelstein; Jan B Vermorken Journal: Oncologist Date: 2017-05-22
Authors: Jung Julie Kang; Vatche Tchekmedyian; Nader Mohammed; Alisa Rybkin; Sarin Kitpanit; Ming Fan; Huili Wang; Stephanie M Lobaugh; Zhigang Zhang; Anna Lee; Linda Chen; Yao Yu; Kaveh Zakeri; Daphna Y Gelblum; Nadeem Riaz; Sean M McBride; C Jillian Tsai; Marc A Cohen; Jennifer R Cracchiolo; Luc G Morris; Bhuvanesh Singh; Snehal Patel; Ian Ganly; Jay O Boyle; Richard J Wong; Juliana Eng; Wanqing Iris Zhi; Kenneth Ng; Alan L Ho; Lara A Dunn; Loren Michel; James V Fetten; David G Pfister; Nancy Y Lee; Eric J Sherman Journal: Int J Cancer Date: 2021-02-27 Impact factor: 7.316
Authors: Sandra I Bril; Abrahim Al-Mamgani; Najiba Chargi; Peter Remeijer; Lot A Devriese; Jan Paul de Boer; Remco de Bree Journal: Head Neck Date: 2021-10-29 Impact factor: 3.821
Authors: Arslan Babar; Neil M Woody; Ahmed I Ghanem; Jillian Tsai; Neal E Dunlap; Matthew Schymick; Howard Y Liu; Brian B Burkey; Eric D Lamarre; Jamie A Ku; Joseph Scharpf; Brandon L Prendes; Nikhil P Joshi; Jimmy J Caudell; Farzan Siddiqui; Sandro V Porceddu; Nancy Lee; Larisa Schwartzman; Shlomo A Koyfman; David J Adelstein; Jessica L Geiger Journal: Curr Oncol Date: 2021-06-30 Impact factor: 3.677
Authors: Ryan T Hughes; Mercedes Porosnicu; Beverly J Levine; Thomas W Lycan; Rachel F Shenker; Bart A Frizzell; Kathryn M Greven Journal: J Med Imaging Radiat Oncol Date: 2021-07-26 Impact factor: 1.667